Literature DB >> 6883400

Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide.

T J Campbell, E M Vaughan Williams.   

Abstract

The voltage- and rate-dependence of the depression of the maximum rate of depolarisation (Vmax) by therapeutic concentrations of flecainide and lorcainide were studied in guinea-pig ventricle by standard microelectrode techniques. At normal resting potentials the drugs produced only minor depression of Vmax in the absence of stimulation ("resting block") but trains of stimuli at inter-stimulus intervals (ISI) less than 4800 ms led to an exponential decline in Vmax to a new plateau over 20 to 50 beats. This "rate-dependent block" (RDB) increased with rate over the range ISI-4800 ms to ISI = 200 ms. The rates of onset of RDB in response to sudden increases in rate were very similar for both drugs and significantly slower than those reported for other anti-arrhythmic drugs. The time constants of recovery from RDB were 15.5 +/- 0.5s for flecainide and 13.2 +/- 1.3s for lorcainide. Both drugs shifted the steady-state relationship between Vmax and membrane potential in the hyperpolarising direction thus producing enhanced depression of Vmax in depolarised cells. It is concluded that these long recovery times may explain the marked depression of conduction of normal sinus beats seen with these drugs. The selective depression of depolarised cells may be of clinical relevance in ischaemic states.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883400     DOI: 10.1093/cvr/17.5.251

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  28 in total

Review 1.  Antiarrhythmics--from cell to clinic: past, present, and future.

Authors:  J C Hancox; K C Patel; J V Jones
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

2.  Effects of potassium channel and Na+-Ca2+ exchange blockers on the responses of slowly adapting pulmonary stretch receptors to hyperinflation in flecainide-treated rats.

Authors:  S Matsumoto; T Nishikawa; S Yoshida; M Ikeda; T Tanimoto; C Saiki; M Takeda
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

3.  Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

4.  Electrophysiological effects of CRE-1087 in guinea-pig ventricular muscles.

Authors:  E Delpón; C Valenzuela; O Pérez; J Tamargo
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

5.  Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells.

Authors:  A O Grant; R Chandra; C Keller; M Carboni; C F Starmer
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

6.  Electrophysiological effects of E-3753, a new antiarrhythmic drug, in guinea-pig ventricular muscle.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

Review 7.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

8.  Vulnerability in an excitable medium: analytical and numerical studies of initiating unidirectional propagation.

Authors:  C F Starmer; V N Biktashev; D N Romashko; M R Stepanov; O N Makarova; V I Krinsky
Journal:  Biophys J       Date:  1993-11       Impact factor: 4.033

9.  Electrophysiological effects of the combination of mexiletine and flecainide in guinea-pig ventricular fibres.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

10.  Electrophysiological effects of flecainide acetate on stretched guinea pig left atrial muscle fibers.

Authors:  D Inoue; T Shirayama; I Omori; M Inoue; R Sakai; K Ishibashi; H Miyazaki; Y Yamahara; T Tatsumi; J Asayama
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.